SNNVF Relative Valuation - Sunniva Inc

Watchlist Manager

Watchlist

Price: 0.0001 USD Market Closed

Market Cap: $46.2m

Relative Value

SNNVF latest financial reports are more than 3 years old.

SNNVF doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of SNNVF.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

What is Relative Valuation?

How is Relative Value calculated?

SNNVF Relative Value

Base Case

Worst Case

Base Case

Best Case

Valuation Multiples

View Details

Multiples Across Competitors

All Multiples

P/S

P/E

EV/EBITDA

EV/EBIT

Forward Multiples

			Market Cap	P/S	P/E	EV/EBITDA	EV/EBIT
CA	S	Sunniva Inc OTC:SNNVF	6.1m USD	0.1	-0.1	-2.3	-1.9
US		Eli Lilly and Co NYSE:LLY	879B USD	13.5	42.6	28.7	30.7
US		Johnson & Johnson NYSE:JNJ	573.4B USD	6.1	21.4	14.9	18.3
CH		Roche Holding AG SIX:ROG	257.8B CHF	4.2	20	11.8	13.3
UK		AstraZeneca PLC LSE:AZN	224B GBP	5.1	29	16.1	22.7
CH		Novartis AG SIX:NOVN	231.4B CHF	5.3	21.2	13.1	16.8
US		Merck & Co Inc NYSE:MRK	286.7B USD	4.4	15.7	9.7	11.9
IE	E	Endo International PLC LSE:0Y5F	240.1B USD	103.6	-82.1	380.1	953.2
DK		Novo Nordisk A/S CSE:NOVO B	1.1T DKK	3.5	10.6	7.9	9.2
US		Pfizer Inc NYSE:PFE	156.1B USD	2.5	20.1	7.7	10.3
US		Bristol-Myers Squibb Co NYSE:BMY	120.2B USD	2.5	17.1	7.2	8.8

				Revenue Growth	P/S to Growth
CA	S	Sunniva Inc OTC:SNNVF	Average P/S: 13.7 0.1	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	13.5	19%	0.7
US		Johnson & Johnson NYSE:JNJ	6.1	6%	1
CH		Roche Holding AG SIX:ROG	4.2	4%	1
UK		AstraZeneca PLC LSE:AZN	5.1	7%	0.7
CH		Novartis AG SIX:NOVN	5.3	5%	1.1
US		Merck & Co Inc NYSE:MRK	4.4	5%	0.9
IE	E	Endo International PLC LSE:0Y5F	103.6	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	3.5	2%	1.8
US		Pfizer Inc NYSE:PFE	2.5	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	2.5	-5%	N/A

				Earnings Growth	PEG
CA	S	Sunniva Inc OTC:SNNVF	Average P/E: 22 Negative Multiple: -0.1	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	42.6	32%	1.3
US		Johnson & Johnson NYSE:JNJ	21.4	7%	3.1
CH		Roche Holding AG SIX:ROG	20	14%	1.4
UK		AstraZeneca PLC LSE:AZN	29	26%	1.1
CH		Novartis AG SIX:NOVN	21.2	14%	1.5
US		Merck & Co Inc NYSE:MRK	15.7	14%	1.1
IE	E	Endo International PLC LSE:0Y5F	Negative Multiple: -82.1	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	10.6	1%	10.6
US		Pfizer Inc NYSE:PFE	20.1	22%	0.9
US		Bristol-Myers Squibb Co NYSE:BMY	17.1	16%	1.1

				EBITDA Growth	EV/EBITDA to Growth
CA	S	Sunniva Inc OTC:SNNVF	Average EV/EBITDA: 49.7 Negative Multiple: -2.3	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	28.7	22%	1.3
US		Johnson & Johnson NYSE:JNJ	14.9	2%	7.4
CH		Roche Holding AG SIX:ROG	11.8	6%	2
UK		AstraZeneca PLC LSE:AZN	16.1	13%	1.2
CH		Novartis AG SIX:NOVN	13.1	5%	2.6
US		Merck & Co Inc NYSE:MRK	9.7	3%	3.2
IE	E	Endo International PLC LSE:0Y5F	380.1	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	7.9	1%	7.9
US		Pfizer Inc NYSE:PFE	7.7	-9%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	7.2	-10%	N/A

				EBIT Growth	EV/EBIT to Growth
CA	S	Sunniva Inc OTC:SNNVF	Average EV/EBIT: 109.5 Negative Multiple: -1.9	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	30.7	22%	1.4
US		Johnson & Johnson NYSE:JNJ	18.3	7%	2.6
CH		Roche Holding AG SIX:ROG	13.3	5%	2.7
UK		AstraZeneca PLC LSE:AZN	22.7	21%	1.1
CH		Novartis AG SIX:NOVN	16.8	9%	1.9
US		Merck & Co Inc NYSE:MRK	11.9	6%	2
IE	E	Endo International PLC LSE:0Y5F	953.2	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	9.2	3%	3.1
US		Pfizer Inc NYSE:PFE	10.3	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	8.8	-7%	N/A

Sunniva Inc
OTC:SNNVF

Relative Value

Valuation Multiples

Multiples Across Competitors

SNNVF Competitors Multiples
Sunniva Inc Competitors

See Also

Company

Help

Tools

Stocks

Sunniva Inc OTC:SNNVF

Relative Value

Valuation Multiples

Multiples Across Competitors

SNNVF Competitors Multiples Sunniva Inc Competitors

See Also

Company

Help

Tools

Stocks

Sunniva Inc
OTC:SNNVF

SNNVF Competitors Multiples
Sunniva Inc Competitors